Judith Anzures-Cabrera
Overview
Explore the profile of Judith Anzures-Cabrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson H, Anzures-Cabrera J, Simuni T, Postuma R, Marek K, Pagano G
Front Aging Neurosci
. 2023 Oct;
15:1232387.
PMID: 37810617
Introduction: To test drugs with the potential to prevent the onset of Parkinson's disease (PD), it is key to identify individuals in the general population at high risk of developing...
2.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....
3.
Szefler S, Roberts G, Rubin A, Zielen S, Kuna P, Alpan O, et al.
Clin Transl Allergy
. 2022 Jul;
12(7):e12176.
PMID: 35846226
Background: Lebrikizumab is a monoclonal antibody that modulates activity of interleukin-13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard-of-care treatment. Methods:...
4.
Jackson H, Anzures-Cabrera J, Taylor K, Pagano G
Front Neurosci
. 2021 Dec;
15:765765.
PMID: 34966256
Currently, no treatments available for Parkinson's disease (PD) can slow PD progression. At the early stage of the disease, only a subset of individuals with PD progress quickly, while the...
5.
Pagano G, Boess F, Taylor K, Ricci B, Mollenhauer B, Poewe W, et al.
Front Neurol
. 2021 Oct;
12:705407.
PMID: 34659081
Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. The study objective was to evaluate the efficacy...
6.
Roth A, Nishimura J, Nagy Z, Gaal-Weisinger J, Panse J, Yoon S, et al.
Blood
. 2020 Jan;
135(12):912-920.
PMID: 31978221
Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and...
7.
Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg C, Anzures-Cabrera J, et al.
Respir Med
. 2018 Feb;
134:143-149.
PMID: 29413502
Background: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of...
8.
Anzures-Cabrera J, Higgins J
Res Synth Methods
. 2015 Jun;
1(1):66-80.
PMID: 26056093
Meta-analyses are fundamental tools for collating and synthesizing large amounts of information, and graphical displays have become the principal tool for presenting the results of multiple studies of the same...
9.
Higgins J, Lane P, Anagnostelis B, Anzures-Cabrera J, Baker N, Cappelleri J, et al.
Res Synth Methods
. 2015 Jun;
4(4):351-66.
PMID: 26053948
Background: Because meta-analyses are increasingly prevalent and cited in the medical literature, it is important that tools are available to assess their methodological quality. When performing an empirical study of...
10.
Lane P, Higgins J, Anagnostelis B, Anzures-Cabrera J, Baker N, Cappelleri J, et al.
Res Synth Methods
. 2015 Jun;
4(4):342-50.
PMID: 26053947
Context: Meta-analyses are regularly used to inform healthcare decisions. Concerns have been expressed about the quality of meta-analyses and, in particular, about those supported by the pharmaceutical industry. Objective: The...